Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease. Chen MH, Lee IC, Chen MH, Hou MC, et al. Ann Rheum Dis 2021;80:1393-1399.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Chen MH, Lee IC, Chen MH, Hou MC, et al. Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease. Ann Rheum Dis 2021;80:1393-1399.
PMID: 34187776